Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry

被引:3
|
作者
Riveira-Martin, Mercedes [1 ,2 ]
Struelens, Lara [3 ]
Iglesias, Jose Munoz [4 ]
Schoonjans, Werner [3 ]
Tabuenca, Olga [4 ]
Nogueiras, Jose Manuel [5 ]
Gomez, Francisco Javier Salvador [6 ]
Medina, Antonio Lopez [6 ,7 ]
机构
[1] Galicia Hlth Res Inst IISGS, Genet Oncol Radiobiol & Radiointeract Res Grp, Vigo, Spain
[2] Univ Complutense Madrid, Med Sch, Dept Radiol Rehabil & Physiotherapy, Madrid, Spain
[3] Belgian Nucl Res Ctr SCK CEN, Mol, Belgium
[4] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept SERGAS, Vigo, Spain
[5] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept GALARIA, Vigo, Spain
[6] Univ Hosp Vigo, Meixoeiro Hosp, Med Phys & RP Dept GALARIA, Vigo, Spain
[7] Univ Vigo, Dept Funct Biol & Hlth Sci, Vigo, Spain
关键词
Lu-177]Lu-DOTA-TATE; Occupational exposure; Nuclear medicine; Equivalent dose; RECEPTOR RADIONUCLIDE THERAPY; NEUROENDOCRINE TUMORS; LU-177; SAFETY; LU-177-DOTATATE; LU-177-OCTREOTATE;
D O I
10.1186/s40658-023-00592-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: The use of lutetium-177 (Lu-177)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of nuclear medicine workers exposed to higher levels of radiation. In recent years, [Lu-177]Lu-DOTA-TATE has begun to be widely used for the treatment of neuroendocrine tumours. However, there are few studies evaluating the occupational radiation exposure during its administration, and there are still some challenges that can result in higher doses to the staff, such as a lack of trained personnel or fully standardised procedures. In response, this study aims to provide a comprehensive analysis of occupational doses to the staff involved in the administration of [Lu-177]Lu-DOTA-TATE.Results: A total of 32 administrations of [Lu-177]Lu-DOTA-TATE (7.4 GBq/session) carried out by a physician and a nurse, were studied. In total, two physicians and four nurses were independently monitored with cumulative (passive) and/or real-time (active) dosemeters. Extremity, eye lens and whole-body doses were evaluated in terms of the dosimetric quantities Hp(0.07), Hp(3) and Hp(10), respectively. It was obtained that lead aprons reduced dose rates and whole-body doses by 71% and 69% for the physicians, respectively, and by 56% and 68% for the nurses. On average, normalised Hp(10) values of 0.65 +/- 0.18 mu Sv/GBq were obtained with active dosimetry, which is generally consistent with passive dosemeters. For physicians, the median of the maximum normalised Hp(0.07) values was 41.5 mu Sv/GBq on the non-dominant hand and 45.2 mu Sv/GBq on the dominant hand. For nurses 15.4 mu Sv/GBq on the non-dominant and 13.9 mu Sv/GBq on the dominant hand. The ratio or correction factor between the maximum dose measured on the hand and the dose measured on the base of the middle/ring finger of the non-dominant hand resulted in a factor of 5/6 for the physicians and 3/4 for the nurses. Finally, maximum normalised Hp(3) doses resulted in 2.02 mu Sv/GBq for physicians and 1.76 mu Sv/GBq for nurses.Conclusions: If appropriate safety measures are taken, the administration of [Lu-177]Lu-DOTA-TATE is a safe procedure for workers. However, regular monitoring is recommended to ensure that the annual dose limits are not exceeded.
引用
收藏
页数:25
相关论文
共 39 条
  • [1] Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry
    Mercedes Riveira-Martin
    Lara Struelens
    José Muñoz Iglesias
    Werner Schoonjans
    Olga Tabuenca
    José Manuel Nogueiras
    Francisco Javier Salvador Gómez
    Antonio López Medina
    EJNMMI Physics, 10
  • [2] Re-treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE of patients with progressive neuroendocrine neoplasm
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Mroz, Adrianna
    Kapusta, Waldemar
    Dmochowska, Beata
    Kaminski, Grzegorz
    NUCLEAR MEDICINE REVIEW, 2023, 26 : 143 - 152
  • [3] Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE
    Fuertes, Teresa Monserrat
    Zorrozua, Borja Santos
    de Zarate, Emilia Rodeno Ortiz
    Montes, Miguel Angel Peinado
    Diaz, Carmen Vigil
    Gabina, Pablo Minguez
    EJNMMI PHYSICS, 2023, 10 (01)
  • [4] Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE
    Prado-Wohlwend, S.
    Bernal-Vergara, J. C.
    Utrera-Costero, A.
    Canon-Sanchez, J. R.
    Agudelo-Cifuentes, M.
    Bello-Arques, P.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (01): : 55 - 65
  • [5] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Ha, Sejin
    Kim, Yong-il
    Oh, Jungsu S.
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Ryu, Jin-Sook
    EJNMMI PHYSICS, 2024, 11 (01)
  • [6] Kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy based on multiple small VOIs
    Kapidzic, Selma Curkic
    Gustafsson, Johan
    Larsson, Erik
    Jessen, Lovisa
    Gleisner, Katarina Sjogreen
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2024, 120
  • [7] Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Kapusta, Waldemar
    Zmudzki, Wawrzyniec
    Mroz, Adrianna
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    CANCERS, 2023, 15 (22)
  • [8] Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics
    Cheng, Jordan
    Zink, Joke
    O'Neill, Edward
    Cornelissen, Bart
    Nonnekens, Julie
    Livieratos, Lefteris
    Terry, Samantha Y. A.
    EJNMMI RESEARCH, 2024, 14 (01):
  • [9] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [10] Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE
    Bruvoll, Ragnar
    Blakkisrud, Johan
    Mikalsen, Lars Tore
    Connelly, James
    Stokke, Caroline
    CANCERS, 2023, 15 (04)